0000000000373977

AUTHOR

M. Schuler

showing 3 related works from this author

Urinary glycosaminoglycans in Graves' ophthalmopathy.

1990

An increased accumulation of glycosaminoglycans (GAG) in retrobulbar tissues has been reported in patients with thyroid eye disease. We examined the quantitative urinary GAG excretion in 101 patients with Graves' ophthalmopathy of different classes, 36 patients with Graves' hyperthyroidism without ophthalmopathy, 14 patients with toxic nodular goitre and 103 control subjects. Glycosaminoglycans were isolated from 24-h urine collections by precipitation with cetylpyridinium chloride and ethanol followed by photometrical quantification of hexuronic acids after reaction with carbazole. In comparison with the control group (15.8, 10.4, 21.6 mg/24 h; median, 25th, 75th percentile) a significant …

AdultMalemedicine.medical_specialtyGoiterAdolescentEndocrinology Diabetes and MetabolismGraves' diseaseUrinary systemUrineGraves' ophthalmopathyExcretionEndocrinologyInternal medicineImmunopathologymedicineHumansAgedGlycosaminoglycansAged 80 and overbusiness.industryThyroidMiddle Agedmedicine.diseaseCombined Modality TherapyGraves DiseaseEndocrinologymedicine.anatomical_structurePrednisoneFemalebusinessGoiter NodularClinical endocrinology
researchProduct

Glycosaminoglycans in Thyroid-Associated Ophthalmopathy

1992

Glycosaminoglycan (GAG) accumulation in the retrobulbar space of patients with thyroid-associated ophthalmopathy (TAO) has been documented in a number of immunohistochemical studies. In order to gain further insight into possible immunopathogenic mechanisms, the influence of humoral immunity on retrobulbar fibroblasts (RF) as GAG producing cells as well as on GAGs themselves was investigated. The effect of lymphocytes on hyaluronic acid (HA) synthesis of RF as well as in turn the influence of RF on lymphocytes were evaluated. In search of methods which would facilitate management of patients with TAO and allow assessment of disease activity, GAGs were determined in both urine and plasma. Im…

medicine.medical_specialtyImmunologyGlycosaminoglycanPathogenesischemistry.chemical_compoundInternal medicineHyaluronic acidExophthalmosHumansImmunology and AllergyMedicineGlycosaminoglycansAutoimmune diseaseImmunity Cellularbiologybusiness.industryThyroidmedicine.diseaseThyroid Diseasesmedicine.anatomical_structureEndocrinologychemistryAntibody FormationImmunologyHumoral immunitybiology.proteinImmunohistochemistryAntibodybusinessAutoimmunity
researchProduct

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

2009

Background: High-level expression of epithelial cell adhesion molecule (EpCAM) is associated with unfavorable prognosis in breast cancer. This study was designed to investigate two doses of the fully human IgG1 anti-EpCAM antibody adecatumumab (MT201) in patients with metastatic breast cancer (MBC). Methods: A total of 109 patients were stratified into high- and low-level EpCAM expression by immunohistochemical staining of primary tumors and subsequently randomly assigned to receive monotherapy with either high- (6 mg/kg every two weeks (q2w)) or low-dose adecatumumab (2 mg/kg/ q2w) until disease progression. Results: No complete or partial tumor responses could be confirmed by central RECI…

OncologyAdultPathologymedicine.medical_specialtyMedizinAntineoplastic AgentsBreast NeoplasmsAntibodies Monoclonal HumanizedDisease-Free SurvivalMetastasischemistry.chemical_compoundBreast cancerAdecatumumabAntigens NeoplasmInternal medicinemedicineHumansNeoplasm MetastasisAgedAged 80 and overDose-Response Relationship Drugbusiness.industryCancerAntibodies MonoclonalEpithelial cell adhesion moleculeHematologyMiddle Agedmedicine.diseaseEpithelial Cell Adhesion MoleculeMetastatic breast cancerTreatment OutcomeOncologychemistryTumor progressionDisease ProgressionFemaleBreast diseasebusinessCell Adhesion Moleculesmedicine.drug
researchProduct